The Braintree firm, which makes a suite of products for blood banking and blood management, posted $152.4 million in fourth-quarter sales, up 10 percent compared with $138.7 million during the same period last year.
Net income for the three months ended March 29 reached $13.9 million, a 1 percent uptick compared with $13.7 million during the fourth quarter of 2008.
For the full year, Haemonetics logged $597.9 million in sales, up 16 percent compared with $516.4 million during fiscal 2008. Annual net income reached $59.3 million, up 14 percent from $52 million last year.
And in a reversal of the usual headlines involving executives and bonuses, all 2,000 Haemonetics employees — except senior management — will receive a 2 percent bonus, roughly equivalent to a week’s pay.
CEO Brian Concannon said the $2.8 million the company plans to lay out for the bonuses is in recognition of workers’ “pivotal role” in the company’s success.
Haemonetics shareholders have less to celebrate. Despite the record numbers, and a $40 million stock repurchasing plan, shares fell more than 5 percent to $49.37 today, after opening at $53.27 and a high of $53.89.